Across several reports this week, a genomic test for prostate cancer called Decipher has drawn attention for a possible new role: helping doctors tell which men with high-risk disease are likely to gain from adding the drug abiraterone to their treatment. The people most affected are men facing the greatest danger from their cancer, for whom each treatment choice carries real weight. Researchers are set to present what they describe as the first evidence that such a test can predict benefit from an added drug, a shift from simply measuring how dangerous a tumour is toward guiding who should re
Genomic Prostate Cancer Test Identifies High-Risk Men Who Benefit From Adding Abiraterone
A test that points to who gains from an add-on drug
Across several reports this week, a genomic test for prostate cancer called Decipher has drawn attention for a possible new role: helping doctors tell which men with high-risk disease are likely to gain from adding the drug abiraterone to their treatment. The people most affected are men facing the greatest danger from their cancer, for whom each treatment choice carries real weight. Researchers are set to present what they describe as the first evidence that such a test can predict benefit from an added drug, a shift from simply measuring how dangerous a tumour is toward guiding who should receive a particular therapy. Whether this promise survives the full data remains to be seen.
This week, several outlets reported the same development on a single news page: a genomic test for prostate cancer, called Decipher, may help doctors identify which high-risk patients would benefit from adding abiraterone to their treatment. Each summary framed it slightly differently. One stressed that the test spots men most likely to die of the disease. Another described it as a way to refine treatment. The clearest claim, however, concerns what researchers plan to present: the first evidence that a prostate test can predict who gains from an added drug.
That distinction matters. Tests that gauge how dangerous a cancer is already play a role in prostate care. A test that points toward who will benefit from a specific add-on therapy would be a different and more directly useful kind of tool. For doctors, the practical question is whom to give abiraterone to, and a result that separates likely beneficiaries from those who may not could shape that choice for men facing the greatest risk.
Yet the available material is thin. The reports do not say how many patients were studied, how large the benefit was, or how much longer men with high Decipher scores lived. Those details will decide how much weight the finding can bear. What comes next is the full data and whether it holds up, and then whether clinical guidelines begin to recommend genomic testing as a guide for prescribing abiraterone.
The headlines gathered on a single news page this week all point to the same development: a genomic test for prostate cancer, called Decipher, may be able to tell doctors which high-risk patients stand to gain from an additional drug, abiraterone.
The Telegraph framed the story around risk, saying the test spots the men most likely to die of the disease. Medical Xpress described it as a diagnostic that could help doctors refine how they treat prostate cancer. Clinical Lab Products said the genomic test predicts which patients benefit from abiraterone therapy. Stock Titan's summary was that Decipher predicts which high-risk patients benefit from adding abiraterone to their treatment.
The most specific claim comes from the account of what researchers plan to do. They will present what is described as the first evidence that a prostate test can predict who benefits from an added drug. That wording matters. It suggests the finding is about prediction of benefit, not only about measuring how dangerous a cancer is. Tests that gauge risk are already part of prostate cancer care. A test that points toward who gains from a specific add-on treatment would be a different kind of tool.
The drug at the center is abiraterone, which is being considered as an addition to treatment for men whose disease carries the highest risk. The practical question for doctors is whom to give it to. A genomic result that sorts patients into those who benefit and those who may not could shape that decision, and the reporting says the test could help clinicians fine-tune treatment for men facing the greatest danger from their cancer.
The material available here is thin. The headlines and summaries do not give the size of the study, the number of patients, the measured benefit, or the setting where the results will be presented. They also do not say how much longer men with a high Decipher score lived, or by how much the drug helped them. Those figures will determine how much weight the finding can carry.
What to watch next is the full data when it is presented, and whether it holds up in the detail. Beyond that, the larger question is whether clinical guidelines come to recommend genomic testing as a guide for prescribing abiraterone.
Envie de l'histoire complète ?
Lire l'original sur Google News ↗
Health & Medicine